The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Medical treatment of gynecomastia that has persisted beyond two years is often ineffective. Gynecomastia is different from "pseudogynecomastia", which is commonly present in men with obesity. Medications such as aromatase inhibitors are effective, even in rare cases of gynecomastia from disorders such as aromatase excess syndrome or Peutz–Jeghers syndrome, but surgical removal of the excess tissue can be needed to correct the condition. In 2019, 24,123 male patients underwent the procedure in the United States, accounting for a 19% increase since 2000.
Root: It is the attached part, consisting of the bulb in the middle and the crura, one crus on either side of the bulb. It lies within the superficial perineal pouch. The crus is attached to the pubic arch. Shaft: The pendulous part of the penis. It has two surfaces: dorsal (posterosuperior in the erect penis) and ventral or urethral (facing downwards and backwards on the flaccid penis). The ventral surface is marked by the penile raphe. The base of the shaft is supported by the suspensory ligament, which is attached to the pubic symphysis. Epithelium of the penis consists of the shaft skin, the foreskin (prepuce), and the preputial mucosa on the inside of it. The foreskin covers and protects the glans and shaft. The epithelium is not attached to the underlying shaft, so it is free to glide to and fro. The human penis is made up of three columns of erectile tissue: two corpora cavernosa lie next to each other (separated by a fibrous septum) on the dorsal side and one corpus spongiosum lies between them on the ventral side. These columns are surrounded by a fibrous layer of connective tissue called the tunica albuginea. The corpora cavernosa are innervated by lesser and greater cavernous nerves and form most of the penis containing blood vessels that fill with blood to help make an erection. The crura are the proximal parts of the corpora cavernosa. The corpus spongiosum is an erectile tissue surrounding the urethra. The proximal parts of the corpus spongiosum form the bulb and the distal ends form the glans penis.
== Research == The availability of accelerator-based BNCT sites allows more opportunities to test BNCT. New therapeutics are also being developed. Future developments are focusing on combining BNCT with other therapies, increasing drug-water solubility and tumor retention, and utilizing BNCT in non-localities. The challenge of tumor heterogeneity is being researched to determine if the variable response to treatment can be addressed.
== History == Molybdenite—the principal ore from which molybdenum is now extracted—was previously known as molybdena. Molybdena was confused with and often used as though it were graphite. Like graphite, molybdenite can be used to blacken a surface or as a solid lubricant. Even when molybdena was distinguishable from graphite, it was still confused with the common lead ore PbS (now called galena); the name comes from Ancient Greek μόλυβδος mólybdos, meaning lead. (The Greek word itself has been proposed as a loanword from Anatolian Luvian and Lydian languages). Although (reportedly) molybdenum was deliberately alloyed with steel in one 14th-century Japanese sword (mfd. c. 1330), that art was never employed widely and was later lost. In the West in 1754, Bengt Andersson Qvist examined a sample of molybdenite and determined that it did not contain lead and thus was not galena. By 1778 Swedish chemist Carl Wilhelm Scheele stated firmly that molybdena was (indeed) neither galena nor graphite. Instead, Scheele correctly proposed that molybdena was an ore of a distinct new element, and from which it might be isolated. Peter Jacob Hjelm successfully isolated a metal he called molybdaenum using carbon and linseed oil in 1781. For the next century, molybdenum had no industrial use. It was relatively scarce, the pure metal was difficult to extract, and the necessary techniques of metallurgy were immature.
Sources: en.wikipedia.org
=== Astina/323F === A sporty, five-door liftback version was called the Familia Astina in Japan. In other markets, it was called 323F and 323 Astina. A luxury version was also sold in Japan as the Eunos 100. The car was produced from 1989 until 1994 before being replaced by the Lantis. A key feature of the Astina/323F is the front end with its pop-up headlights. Depending on the market, there were carbureted or fuel injected SOHC/DOHC versions available of the 1.5, 1.6 and 1.8 L petrol engines. Unlike the standard Familia saloons and three-door hatchback, the Astina never came from the factory with a turbo, diesel or all-wheel drive option. Taillight arrangement varies from market to market, the main difference being the third brake light in the spoiler and two brake lights per cluster (Japanese spec), rather than one. Compared to the Eunos 100, the Familia Astina has some differences, such as a different trunk garnish, a shorter spoiler, available with SOHC engine options, and lacked the optional digital speedometer. In the UK the 323F was launched with 1.6 L 16-valve in either LX, GLX or GLXi trim or as 1.8i 16v GT. In Indonesia it is called Astina GT and RX3 (a special model featured aero kits), it came standard with a 1.8 L DOHC BP engine and a digital speedometer from the JDM Eunos 100. The 323 Astina GLX was sold in South America as well, specifically in Colombia, Chile and Argentina, with 1.6 L SOHC engine, in carbureted version.
== Biography == After migrating to America, Banki graduated from the University of California, Berkeley and subsequently earned a PhD in chemical engineering with a focus on biotechnology from Princeton University. He has published numerous scientific articles and a biotechnology book. After completing his PhD, he worked as a management consultant at the New York City office of McKinsey & Company. In January 2010, Banki was arrested and prosecuted by the United States Attorney's office in New York City. He was charged with violating US sanctions against Iran. He spent 22 months in prison before winning his case on appeal in the Second Circuit Court of Appeals, with all charges against him related to the sanctions being dismissed. After his release Banki earned a Master of Business Administration from the University of California, Los Angeles, and worked at NBCUniversal.
Dimethyltryptamine is an indole alkaloid derived from the shikimate pathway. Its biosynthesis is relatively simple and summarized in the adjacent picture. In plants, the parent amino acid L-tryptophan is produced endogenously where in animals L-tryptophan is an essential amino acid coming from diet. No matter the source of L-tryptophan, the biosynthesis begins with its decarboxylation by an aromatic amino acid decarboxylase (AADC) enzyme (step 1). The resulting decarboxylated tryptophan analogue is tryptamine. Tryptamine then undergoes a transmethylation (step 2): the enzyme indolethylamine-N-methyltransferase (INMT) catalyzes the transfer of a methyl group from cofactor S-adenosylmethionine (SAM), via nucleophilic attack, to tryptamine. This reaction transforms SAM into S-adenosylhomocysteine (SAH), and gives the intermediate product N-methyltryptamine (NMT). NMT is in turn transmethylated by the same process (step 3) to form the end product N,N-dimethyltryptamine. Tryptamine transmethylation is regulated by two products of the reaction: SAH, and DMT were shown ex vivo to be among the most potent inhibitors of rabbit INMT activity. This transmethylation mechanism has been repeatedly and consistently proven by radiolabeling of SAM methyl group with carbon-14 ((14C-CH3)SAM).
Sources: en.wikipedia.org
Plastination is a technique used in anatomy to conserve bodies or body parts. The water and fat are replaced by certain plastics, yielding specimens that can be touched, do not smell or decay, and even retain most microscopic properties of the original sample. The technique was invented by Gunther von Hagens when working at the anatomical institute of the Heidelberg University in 1978. Von Hagens patented the technique in several countries and was heavily involved in its promotion, especially as the creator and director of the Body Worlds traveling exhibitions, exhibiting plastinated human bodies internationally. He also founded and directed the Institute for Plastination in Heidelberg. More than 40 institutions worldwide have facilities for plastination, mainly for medical research and study, and most affiliated to the International Society for Plastination.
=== Glucagon === If the blood glucose level falls to dangerously low levels (as during very heavy exercise or lack of food for extended periods), the alpha cells of the pancreas release glucagon, a peptide hormone which travels through the blood to the liver, where it binds to glucagon receptors on the surface of liver cells and stimulates them to break down glycogen stored inside the cells into glucose (this process is called glycogenolysis). The cells release the glucose into the bloodstream, increasing blood sugar levels. Hypoglycemia, the state of having low blood sugar, is treated by restoring the blood glucose level to normal by the ingestion or administration of dextrose or carbohydrate foods. It is often self-diagnosed and self-medicated orally by the ingestion of balanced meals. In more severe circumstances, it is treated by injection or infusion of glucagon.
"RCSB Protein Data Bank - Structure Summary for 1Z7C - Crystal Structure of Human Placental Lactogen". "Human Chorionic Somatomammotropin Enhancer Function Is Mediated by Cooperative Binding of TEF-1 and CSEF-1 to Multiple, Low-Affinity Binding Sites". Archived from the original on 2008-07-05.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.